Wiki » History » Version 68
Jason Bobe, 03/10/2010 03:40 PM
1 | 36 | Jason Bobe | = Genotype + Environment = Trait Evidence (GET-E) Database = |
---|---|---|---|
2 | 1 | Jason Bobe | |
3 | 38 | Jason Bobe | The '''GET-E''' project was started by Abraham Rosenbaum, Joe Thakuria, Xiaodi Wu and Alexander Wait Zaranek to help the [http://personalgenomes.org Personal Genome Project], the clinical genetics community, and, the general public interpret individual genomes. The database is closely integrated with [wiki:Trait-o-matic]. |
4 | 1 | Jason Bobe | |
5 | You can find the PGP production server at: |
||
6 | * http://evidence.personalgenomes.org |
||
7 | |||
8 | A development sandbox can be found at: |
||
9 | * http://evidence-dev.personalgenomes.org |
||
10 | |||
11 | 37 | Jason Bobe | Many contributors helped make '''GET-E''' possible. You can find specific contributions at: |
12 | 1 | Jason Bobe | * http://evidence.personalgenomes.org/editors |
13 | |||
14 | 38 | Jason Bobe | Please help the project by editing the database, writing software tools that use the database (eg. Trait-o-matic/AETAS) or by making suggestions on the wiki! |
15 | 1 | Jason Bobe | |
16 | 28 | Jason Bobe | == Field Descriptions and Editing Guidelines == |
17 | 19 | Jason Bobe | === Short Summary === |
18 | * free text providing a one line summary of clinical action to be undertaken given this variant (possibly modified by known phenotypes). |
||
19 | |||
20 | 64 | Jason Bobe | === Variant Evidence === |
21 | 63 | Jason Bobe | Each of these fields is a sliding scale of 0-5 where 0 represents no evidence and 5 strong evidence within the given category. Where the data is not entered the default is N/A. When Genetests and/or the literature correlate this variant with a number of phenotypes the impact should be reported for the most extreme condition |
22 | 58 | Jason Bobe | a. Computational: One star for each consistent prediction and one star subtracted for conflicting results from: |
23 | 26 | Jason Bobe | i. evolutionary conservation (minimum of three species) |
24 | i. presence in active domain |
||
25 | 27 | Jason Bobe | i. SIFT |
26 | i. !PolyPhen |
||
27 | 44 | Jason Bobe | i. NBLOSUM >= 2 |
28 | 27 | Jason Bobe | i. GVGD |
29 | 23 | Jason Bobe | i. Other variants in this gene cause similar disease |
30 | i. etc... |
||
31 | 58 | Jason Bobe | a. Functional: One star for each experiment supporting the result, and penalize one star for conflicting results from: |
32 | 23 | Jason Bobe | i. enzyme extracts |
33 | i. cell lines |
||
34 | i. animal models |
||
35 | i. etc... |
||
36 | 50 | Jason Bobe | a. Case/Control: A combination of odds ratio and significance test (currently using Fisher's Exact Test). For protective alleles, use inverse OR = 1 / OR. Do not count related individuals, count probands -- ie. one per family |
37 | 40 | Jason Bobe | i. 0 stars if no higher ranking is allowed |
38 | 41 | Jason Bobe | i. 1 star if OR>1 and significance <= 0.1 |
39 | i. 2 stars if OR>=1.5 and significance <= 0.05 |
||
40 | 45 | Jason Bobe | i. 3 stars if OR>=2 and significance <= 0.025 |
41 | i. 4 stars if OR>=3 and significance <= 0.01 |
||
42 | i. 5 stars if OR>=5 and significance <= 0.0001 |
||
43 | 24 | Jason Bobe | a. Familial Disease Segregation |
44 | 25 | Jason Bobe | i. 0 stars for no segregation (LOD < -2) |
45 | 24 | Jason Bobe | i. 1 star if segregation exists in one family pedigree |
46 | i. 2 stars for segregation in more than one family with some conflicting information (e.g. asymptomatic carrier of young age or possibility of second causative mutation) |
||
47 | i. 3 stars for more than one family no conflicting information |
||
48 | i. 4 stars for LOD > 2 |
||
49 | 1 | Jason Bobe | i. 5 stars for LOD > 3 |
50 | 63 | Jason Bobe | |
51 | 64 | Jason Bobe | === Clinical Importance === |
52 | 63 | Jason Bobe | As with the Variant Quality section, each of these fields is a sliding scale of 0-5. These two categories are not applicable for benign and protective variants. |
53 | |||
54 | 68 | Jason Bobe | a. Disease severity: downgraded according to disease penetrance (eg. Crohn's disease would be moderate or severe, but "increased susceptibility" could only mean that the chances are increased by ~.15% and so would be called mild). For pharmacogenetic variants this is the severity of using the wrong drug/dosage. |
55 | 51 | Jason Bobe | i. 0 stars for benign |
56 | 60 | Jason Bobe | i. 1 star for very low expectation of having symptoms for this genotype, very low penetrance (eg. Susceptibility to crohn's with OR = 4.5, causing a ~.2% risk of Crohn's) |
57 | i. 2 stars for mild effect on quality of life or unlikely to be symptomatic (Cystinuria) |
||
58 | i. 3 stars for moderate effect on quality of life (eg. Familial mediterranean fever) |
||
59 | i. 4 stars for severe effect: causes serious disability or reduces life expectancy (eg. Sickle-cell, Stargardt's disease) |
||
60 | i. 5 stars for very severe effect: early lethal (eg. Familial adenomatous polypopsis, adrenoleukodystrophy) |
||
61 | 51 | Jason Bobe | a. Treatability: |
62 | i. 0 stars for no clinical evidence supporting intervention (eg. PAF acetylhydrolase deficiency) |
||
63 | i. 1 star for uncurable: treatment only to alleviate symptoms (eg. adrenoleukodystrophy) |
||
64 | 59 | Jason Bobe | i. 2 stars for potentially treatable: Treatment is in development or controversial |
65 | i. 3 stars for treatable but a significant fraction do not require treatment (Cystinuria) |
||
66 | 1 | Jason Bobe | i. 4 stars for treatable: Standard treatment reduces the amount of mortality/morbidity but does not eliminate it (eg. Sickle-cell disease) |
67 | 54 | Jason Bobe | i. 5 stars for extremely treatable: Well-established treatment essentially eliminates the effect of the disease (eg. PKU) |
68 | 1 | Jason Bobe | |
69 | 47 | Jason Bobe | === Impact === |
70 | 64 | Jason Bobe | This is filled in as one of the following: |
71 | 32 | Jason Bobe | a. Pathogenic: Causative for disease. |
72 | a. Benign: No clinically significant phenotype. |
||
73 | 1 | Jason Bobe | a. Protective: Protective from disease. |
74 | a. Pharmacogenetic: Clinically significant phenotype in the presence of a pharmacological agent. |
||
75 | a. NR: Not reviewed. |
||
76 | |||
77 | 64 | Jason Bobe | In addition to these categories, up to two qualifiers will be added automatically according to the variant quality scores. The first, "evidence", is based on the four "Variant Evidence" categories. The second, "importance", is based on the two "Clinical Importance" categories (not applicable for benign and protective categories). |
78 | 1 | Jason Bobe | |
79 | 64 | Jason Bobe | An example for "pathogenic" follows: |
80 | || - ||'''low evidence'''||'''moderate evidence'''||'''high evidence''' |
||
81 | ||'''low importance'''|| uncertain pathogenic || likely pathogenic || pathogenic |
||
82 | ||'''moderate importance'''|| uncertain important pathogenic || likely important pathogenic || important pathogenic |
||
83 | ||'''high importance'''|| uncertain very important pathogenic || likely very important pathogenic || very important pathogenic |
||
84 | 61 | Jason Bobe | |
85 | 64 | Jason Bobe | Criteria for evidence: |
86 | a. For no qualifier (ie, well-established): (1) at least 4 stars in either "Case/control evidence" or "Familial evidence" and (2) at least eight stars total |
||
87 | 66 | Jason Bobe | a. For "likely": (1) at least 3 stars in either "Case/control evidence" or "Familial evidence" and (2) at least five stars total |
88 | 64 | Jason Bobe | a. Otherwise "uncertain" |
89 | |||
90 | Criteria for importance (not used for benign and protective): |
||
91 | 66 | Jason Bobe | a. For "very important": (1) at least 3 stars in severity and at least 4 stars in treatability, or (2) at least 4 stars in severity |
92 | a. For "important": (1) at least 2 stars in severity and at least 3 stars in treatability, or (2) at least 3 stars in either severity |
||
93 | 65 | Jason Bobe | a. Otherwise no qualifier |
94 | 39 | Jason Bobe | |
95 | 19 | Jason Bobe | When Genetests and/or the literature give multiple phenotypes for a variant, the impact should be reported for the most extreme condition and annotated as such in the ''short summary''. In the future we hope to list different phenotypes separately. |
96 | |||
97 | === Inheritance Pattern === |
||
98 | a. Dominant |
||
99 | a. Recessive |
||
100 | a. Other: A defined form of inheritance that is neither dominant or recessive (e.g. modifier, co-dominant, incomplete penetrance). These variants will get prioritized due to their potential phenotypic affect should the additional factors be present. |
||
101 | a. Undefined: Undefined in the literature. |
||
102 | a. Unknown: The default value for all variants and all variants without literature. |
||
103 | |||
104 | 22 | Jason Bobe | === Summary of published research, and additional commentary === |
105 | 1 | Jason Bobe | * Free text providing a comprehensive review of the variant including youngest age of onset, oldest age of onset and oldest asymptomatic individual. |
106 | 21 | Jason Bobe | |
107 | 22 | Jason Bobe | === Allele Frequency === |
108 | 21 | Jason Bobe | * Automatically generated frequencies for the !HapMap Project, 1000 Genomes Project and the weighted average of the two. Sub-population frequencies and homozygous/heterozygous break-downs are currently not shown. |
109 | |||
110 | === Publications === |
||
111 | |||
112 | * User-entered publications and user entered synopses of the relevant details from the publication. A short summary is also entered for each paper (as above). |
||
113 | |||
114 | === Genomes === |
||
115 | |||
116 | * Automatically generated list of all genomes from Trait-o-matic in which this variant is seen. Additionally, specific actions taken by each individual harboring the variant can be reported. |
||
117 | |||
118 | === Other External References === |
||
119 | 13 | Jason Bobe | These are automatically generated by web "robots": |
120 | 12 | Jason Bobe | a. dbSNP: The link to the dbSNP entry for this nucleotide position (for this nucleotide change?) |
121 | a. Genetests: Link to all clinical laboratories performing diagnostic tests on this gene and the list of diseases that the labs are looking for. |
||
122 | 21 | Jason Bobe | a. Web Search Results: A web search for this exact variant using the Yahoo search engine |
123 | |||
124 | === Edit History === |
||
125 | 20 | Jason Bobe | * Automatically generated history of all page edits with the contributor's name. |
126 | |||
127 | == To Do == |
||
128 | 3 | Jason Bobe | * [wiki:GET-Evidence/23andWe] |
129 | 1 | Jason Bobe | |
130 | == Suggestions == |
||
131 | |||
132 | * your suggestion here. |